Sex hormone-binding globulin gene expression in the liver

Drugs and the metabolic syndrome

Michel Pugeat, Nancy Nader, Kevin Hogeveen, Gérald Raverot, Henri Déchaud, Catherine Grenot

Research output: Contribution to journalReview article

70 Citations (Scopus)

Abstract

Sex hormone-binding globulin (SHBG) is the main transport binding protein for sex steroid hormones in plasma and regulates their accessibility to target cells. Plasma SHBG is secreted by the liver under the control of hormones and nutritional factors. In the human hepatoma cell line (HepG2), thyroid and estrogenic hormones, and a variety of drugs including the antioestrogen tamoxifen, the phytoestrogen, genistein and mitotane (Op′DDD) increase SHBG production and SHBG gene promoter activity. In contrast, monosaccharides (glucose or fructose) effectively decrease SHBG expression by inducing lipogenesis, which reduces hepatic HNF-4α levels, a transcription factor that play a critical role in controlling the SHBG promoter. Interestingly, diminishing hepatic lipogenesis and free fatty acid liver biosynthesis also appear to be associated with the positive effects of thyroid hormones and PPARγ antagonists on SHBG expression. This mechanism provides a biological explanation for why SHBG is a sensitive biomarker of insulin resistance and the metabolic syndrome, and why low plasma SHBG levels are a risk factor for developing hyperglycemia and type 2 diabetes, especially in women. These important advances in our knowledge of the regulation of SHBG expression in the liver open new approaches for identifying and preventing metabolic disorder-associated diseases early in life.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalMolecular and Cellular Endocrinology
Volume316
Issue number1
DOIs
Publication statusPublished - 5 Mar 2010
Externally publishedYes

Fingerprint

Sex Hormone-Binding Globulin
Gene expression
Liver
Gene Expression
Pharmaceutical Preparations
Lipogenesis
Thyroid Hormones
Plasmas
Carrier Proteins
Mitotane
Hormones
Hormone Antagonists
Phytoestrogens
Peroxisome Proliferator-Activated Receptors
Estrogen Receptor Modulators
Monosaccharides
Genistein
Biosynthesis
Gonadal Steroid Hormones
Biomarkers

Keywords

  • Diabetes
  • Fructose
  • Metabolic syndrome
  • Risk factor
  • Sex steroid hormones
  • SHBG

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Cite this

Sex hormone-binding globulin gene expression in the liver : Drugs and the metabolic syndrome. / Pugeat, Michel; Nader, Nancy; Hogeveen, Kevin; Raverot, Gérald; Déchaud, Henri; Grenot, Catherine.

In: Molecular and Cellular Endocrinology, Vol. 316, No. 1, 05.03.2010, p. 53-59.

Research output: Contribution to journalReview article

Pugeat, Michel ; Nader, Nancy ; Hogeveen, Kevin ; Raverot, Gérald ; Déchaud, Henri ; Grenot, Catherine. / Sex hormone-binding globulin gene expression in the liver : Drugs and the metabolic syndrome. In: Molecular and Cellular Endocrinology. 2010 ; Vol. 316, No. 1. pp. 53-59.
@article{7f017a5d94884acc89cc73fb40a892da,
title = "Sex hormone-binding globulin gene expression in the liver: Drugs and the metabolic syndrome",
abstract = "Sex hormone-binding globulin (SHBG) is the main transport binding protein for sex steroid hormones in plasma and regulates their accessibility to target cells. Plasma SHBG is secreted by the liver under the control of hormones and nutritional factors. In the human hepatoma cell line (HepG2), thyroid and estrogenic hormones, and a variety of drugs including the antioestrogen tamoxifen, the phytoestrogen, genistein and mitotane (Op′DDD) increase SHBG production and SHBG gene promoter activity. In contrast, monosaccharides (glucose or fructose) effectively decrease SHBG expression by inducing lipogenesis, which reduces hepatic HNF-4α levels, a transcription factor that play a critical role in controlling the SHBG promoter. Interestingly, diminishing hepatic lipogenesis and free fatty acid liver biosynthesis also appear to be associated with the positive effects of thyroid hormones and PPARγ antagonists on SHBG expression. This mechanism provides a biological explanation for why SHBG is a sensitive biomarker of insulin resistance and the metabolic syndrome, and why low plasma SHBG levels are a risk factor for developing hyperglycemia and type 2 diabetes, especially in women. These important advances in our knowledge of the regulation of SHBG expression in the liver open new approaches for identifying and preventing metabolic disorder-associated diseases early in life.",
keywords = "Diabetes, Fructose, Metabolic syndrome, Risk factor, Sex steroid hormones, SHBG",
author = "Michel Pugeat and Nancy Nader and Kevin Hogeveen and G{\'e}rald Raverot and Henri D{\'e}chaud and Catherine Grenot",
year = "2010",
month = "3",
day = "5",
doi = "10.1016/j.mce.2009.09.020",
language = "English",
volume = "316",
pages = "53--59",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Sex hormone-binding globulin gene expression in the liver

T2 - Drugs and the metabolic syndrome

AU - Pugeat, Michel

AU - Nader, Nancy

AU - Hogeveen, Kevin

AU - Raverot, Gérald

AU - Déchaud, Henri

AU - Grenot, Catherine

PY - 2010/3/5

Y1 - 2010/3/5

N2 - Sex hormone-binding globulin (SHBG) is the main transport binding protein for sex steroid hormones in plasma and regulates their accessibility to target cells. Plasma SHBG is secreted by the liver under the control of hormones and nutritional factors. In the human hepatoma cell line (HepG2), thyroid and estrogenic hormones, and a variety of drugs including the antioestrogen tamoxifen, the phytoestrogen, genistein and mitotane (Op′DDD) increase SHBG production and SHBG gene promoter activity. In contrast, monosaccharides (glucose or fructose) effectively decrease SHBG expression by inducing lipogenesis, which reduces hepatic HNF-4α levels, a transcription factor that play a critical role in controlling the SHBG promoter. Interestingly, diminishing hepatic lipogenesis and free fatty acid liver biosynthesis also appear to be associated with the positive effects of thyroid hormones and PPARγ antagonists on SHBG expression. This mechanism provides a biological explanation for why SHBG is a sensitive biomarker of insulin resistance and the metabolic syndrome, and why low plasma SHBG levels are a risk factor for developing hyperglycemia and type 2 diabetes, especially in women. These important advances in our knowledge of the regulation of SHBG expression in the liver open new approaches for identifying and preventing metabolic disorder-associated diseases early in life.

AB - Sex hormone-binding globulin (SHBG) is the main transport binding protein for sex steroid hormones in plasma and regulates their accessibility to target cells. Plasma SHBG is secreted by the liver under the control of hormones and nutritional factors. In the human hepatoma cell line (HepG2), thyroid and estrogenic hormones, and a variety of drugs including the antioestrogen tamoxifen, the phytoestrogen, genistein and mitotane (Op′DDD) increase SHBG production and SHBG gene promoter activity. In contrast, monosaccharides (glucose or fructose) effectively decrease SHBG expression by inducing lipogenesis, which reduces hepatic HNF-4α levels, a transcription factor that play a critical role in controlling the SHBG promoter. Interestingly, diminishing hepatic lipogenesis and free fatty acid liver biosynthesis also appear to be associated with the positive effects of thyroid hormones and PPARγ antagonists on SHBG expression. This mechanism provides a biological explanation for why SHBG is a sensitive biomarker of insulin resistance and the metabolic syndrome, and why low plasma SHBG levels are a risk factor for developing hyperglycemia and type 2 diabetes, especially in women. These important advances in our knowledge of the regulation of SHBG expression in the liver open new approaches for identifying and preventing metabolic disorder-associated diseases early in life.

KW - Diabetes

KW - Fructose

KW - Metabolic syndrome

KW - Risk factor

KW - Sex steroid hormones

KW - SHBG

UR - http://www.scopus.com/inward/record.url?scp=72549099341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549099341&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2009.09.020

DO - 10.1016/j.mce.2009.09.020

M3 - Review article

VL - 316

SP - 53

EP - 59

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1

ER -